Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 2
2014 2
2016 1
2017 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

5 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
HLA-DRα1 constructs block CD74 expression and MIF effects in experimental autoimmune encephalomyelitis.
Meza-Romero R, Benedek G, Yu X, Mooney JL, Dahan R, Duvshani N, Bucala R, Offner H, Reiter Y, Burrows GG, Vandenbark AA. Meza-Romero R, et al. J Immunol. 2014 May 1;192(9):4164-73. doi: 10.4049/jimmunol.1303118. Epub 2014 Mar 28. J Immunol. 2014. PMID: 24683185 Free PMC article.
CD74, the cell-surface form of the MHC class II invariant chain, is a key inflammatory factor that is involved in various immune-mediated diseases as part of the macrophage migration inhibitory factor (MIF) binding complex. ...We found that DRα1 directly inhibited b
CD74, the cell-surface form of the MHC class II invariant chain, is a key inflammatory factor that is involved in various immune-medi
Partial MHC class II constructs inhibit MIF/CD74 binding and downstream effects.
Benedek G, Meza-Romero R, Andrew S, Leng L, Burrows GG, Bourdette D, Offner H, Bucala R, Vandenbark AA. Benedek G, et al. Eur J Immunol. 2013 May;43(5):1309-21. doi: 10.1002/eji.201243162. Epub 2013 Apr 10. Eur J Immunol. 2013. PMID: 23576302 Free PMC article.
MIF and its receptor, CD74, are pivotal regulators of the immune system. Here, we demonstrate for the first time that partial MHC class II constructs comprised of linked β1α1 domains with covalently attached antigenic peptides (also referred to as recombin
MIF and its receptor, CD74, are pivotal regulators of the immune system. Here, we demonstrate for the first time that partial
A novel regulatory pathway for autoimmune disease: binding of partial MHC class II constructs to monocytes reduces CD74 expression and induces both specific and bystander T-cell tolerance.
Vandenbark AA, Meza-Romero R, Benedek G, Andrew S, Huan J, Chou YK, Buenafe AC, Dahan R, Reiter Y, Mooney JL, Offner H, Burrows GG. Vandenbark AA, et al. J Autoimmun. 2013 Feb;40:96-110. doi: 10.1016/j.jaut.2012.08.004. Epub 2012 Sep 29. J Autoimmun. 2013. PMID: 23026773 Free PMC article.
Treatment with partial (p)MHC class II-β1α1 constructs (also referred to as recombinant T-cell receptor ligands - RTL) linked to antigenic peptides can induce T-cell tolerance, inhibit recruitment of inflammatory cells and reverse autoimmune diseases. ...Binding of …
Treatment with partial (p)MHC class II-β1α1 constructs (also referred to as recombinant T-cell receptor ligands - RTL) linked …
DRα1-MOG-35-55 Reduces Permanent Ischemic Brain Injury.
Wang J, Ye Q, Xu J, Benedek G, Zhang H, Yang Y, Liu H, Meza-Romero R, Vandenbark AA, Offner H, Gao Y. Wang J, et al. Transl Stroke Res. 2017 Jun;8(3):284-293. doi: 10.1007/s12975-016-0514-2. Epub 2016 Dec 17. Transl Stroke Res. 2017. PMID: 27988839 Free PMC article.
The human leukocyte antigen-DRalpha1 domain linked to MOG-35-55 peptide (DRalpha1-MOG-35-55) is a partial major histocompatibility complex (MHC) class II construct which can inhibit neuroantigen-specific T cells and block binding of the cytokine/chemokine macrophage …
The human leukocyte antigen-DRalpha1 domain linked to MOG-35-55 peptide (DRalpha1-MOG-35-55) is a partial major histocompatibility complex ( …
A novel HLA-DRα1-MOG-35-55 construct treats experimental stroke.
Benedek G, Zhu W, Libal N, Casper A, Yu X, Meza-Romero R, Vandenbark AA, Alkayed NJ, Offner H. Benedek G, et al. Metab Brain Dis. 2014 Mar;29(1):37-45. doi: 10.1007/s11011-013-9440-0. Metab Brain Dis. 2014. PMID: 24122483 Free PMC article.
Infarct volumes were quantified after 96 h reperfusion and immune cells from the periphery and CNS were evaluated for expression of CD74 and other cell surface, cytokine and pathway markers. ...Furthermore, DRα1-MOG-35-55 bound to CD74 on monocytes and blo
Infarct volumes were quantified after 96 h reperfusion and immune cells from the periphery and CNS were evaluated for expression of …
Feedback